Weight Loss On Wegovy UK - From £124.99 | Cured Pharmacy

Clinically Proven UK Registered Pharmacy

Cheapest Weight Loss On Wegovy UK Price - From £124.99

Get Wegovy at the cheapest UK price from £124.99 with £20 off first orders using code Weightlossnew.

UK-registered clinical team
Confidential and secure
No GP visit needed
Next-day delivery included — no hidden costs or surprise charges
Start Your Free Consultation

Takes less than 2 minutes to complete 100% online

Weightlossnew £20 off for new customers

Treatment from £124.99

Genuine Products
UK-licensed only
Fast Delivery
Next-day available
Expert Advice
UK pharmacists
Woman using Cured Pharmacy online consultation for weight loss treatment

Check your BMI

Height 175 cm
Weight 82 kg

Your BMI

26.8
Start Free Consultation

Free · BMI thresholds shown are illustrative. Final eligibility is confirmed by a UK prescriber during your free consultation.

LIVE PRICING

Our Pricing

Pricing Disclaimer: Prices on some pages may not be up to date — the live pricing table below and pricing shown during consultation are official current prices and take precedence over any other figures on the site.

Mounjaro (Tirzepatide)
Weeks 1–4

2.5mg

1 pen • 4 Weeks

£145 £124.99

£31.25 / Per Week

Your starting dose – designed to help your body adjust gently to treatment

⭐ Future Orders at £145
Start Consultation
Mounjaro (Tirzepatide)
Weeks 5–8

5mg

1 pen • 4 Weeks

£179 £159.00

£39.75 / Per Week

First step up – builds on your progress as your body adapts to treatment

⭐ Future Orders at £179
Start Consultation
Mounjaro (Tirzepatide)
Weeks 9–12

7.5mg

1 pen • 4 Weeks

£220 £200.00

£50.00 / Per Week

Mid-range dose – for continued progression and enhanced results

⭐ Future Orders at £220
Start Consultation
Mounjaro (Tirzepatide)
Weeks 13–16

10mg

1 pen • 4 Weeks

£245 £225.00

£56.25 / Per Week

Higher strength dose – supports significant weight loss progress

⭐ Future Orders at £245
Start Consultation
Mounjaro (Tirzepatide)
Weeks 17–20

12.5mg

1 pen • 4 Weeks

£270 £250.00

£62.50 / Per Week

Advanced dose – for patients requiring stronger therapeutic effect

⭐ Future Orders at £270
Start Consultation
Mounjaro (Tirzepatide)
Weeks 21+

15mg

1 pen • 4 Weeks

£287 £267.00

£66.75 / Per Week

Maximum dose – the highest available strength for optimal results

⭐ Future Orders at £287
Start Consultation
Wegovy (Semaglutide)
Weeks 1–4

0.25mg

1 pen • 4 Weeks

£89 £69.00

£17.25 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £89
Start Consultation
Wegovy (Semaglutide)
Weeks 5–8

0.5mg

1 pen • 4 Weeks

£109 £89.00

£22.25 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £109
Start Consultation
Wegovy (Semaglutide)
Weeks 9–12

1mg

1 pen • 4 Weeks

£119 £99.00

£24.75 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £119
Start Consultation
Wegovy (Semaglutide)
Weeks 13–16

1.7mg

1 pen • 4 Weeks

£169 £149.00

£37.25 / Per Week

Higher strength – supports accelerated weight loss progress

⭐ Future Orders at £169
Start Consultation
Wegovy (Semaglutide)
Weeks 17+

2.4mg

1 pen • 4 Weeks

£199 £179.00

£44.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199
Start Consultation
Wegovy (Oral Pill)
Weeks 1–4

1.5mg

1 pen • 4 Weeks

£83.00 £63.00

£20.75 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £83.00
Start Consultation
Wegovy (Oral Pill)
Weeks 5–8

4mg

1 pen • 4 Weeks

£110.00 £90.00

£27.50 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £110.00
Start Consultation
Wegovy (Oral Pill)
Weeks 9–12

9mg

1 pen • 4 Weeks

£140.00 £120.00

£35.00 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £140.00
Start Consultation
Wegovy (Oral Pill)
Weeks 13+

25mg

1 pen • 4 Weeks

£199.00 £179.00

£49.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199.00
Start Consultation

Weight Loss On Wegovy: Clinical Evidence and UK Patient Outcomes

Weight loss on Wegovy (semaglutide 2.4mg) represents one of the most significant advances in obesity management available through UK pharmacies. In the landmark STEP clinical trial programme, patients achieved an average weight reduction of 14.9% over 68 weeks when combining Wegovy with lifestyle modifications [1]. At Cured Pharmacy, our superintendent pharmacist Tarun Kumar (GPhC 2233073) and clinical team provide evidence-based prescribing for patients seeking medically supervised weight management with this MHRA-licensed treatment.

Clinical Evidence for Weight Loss On Wegovy in UK Trials

The STEP 1 trial demonstrated that adults using Wegovy achieved a mean weight reduction of 14.9% compared to 2.4% with placebo over 68 weeks, with 86.4% of participants losing at least 5% of their baseline body weight [1]. This once-weekly injectable semaglutide works by mimicking GLP-1, a naturally occurring hormone that regulates appetite and food intake through central nervous system pathways.

In the UK-inclusive STEP 3 trial, which combined Wegovy with intensive behavioural therapy, participants lost an average of 16% of their initial body weight [2]. These outcomes represent substantial improvements over previous weight management medications, positioning semaglutide as a first-line pharmacological option for adults with a BMI of 30 kg/m² or above, or 27 kg/m² with weight-related comorbidities, subject to prescriber assessment.

Real-world data from UK prescribing patterns shows that patients typically begin noticing appetite suppression within the first week of treatment, with measurable weight reduction appearing by week 4 of the dose escalation schedule [3]. The gradual titration protocol—starting at 0.25mg weekly and increasing to the maintenance dose of 2.4mg over 16-20 weeks—minimises gastrointestinal side effects whilst optimising treatment adherence.

STEP Trial Programme: Weight Loss On Wegovy Across Patient Populations

The STEP 2 trial specifically evaluated weight loss on Wegovy in adults with type 2 diabetes, demonstrating a 9.6% average weight reduction compared to 3.4% with placebo [2]. Whilst this represents slightly lower weight loss than in non-diabetic populations, the concurrent improvements in HbA1c levels (average reduction of 1.6%) highlight semaglutide's dual metabolic benefits.

STEP 4 examined weight maintenance after initial loss, showing that participants who continued Wegovy maintained their weight reduction, whilst those switched to placebo regained 6.9% of their body weight on average [1]. This underscores the importance of ongoing treatment for sustained weight management, as obesity is recognised as a chronic relapsing condition requiring long-term pharmacological support.

Expected Timeline for Weight Loss On Wegovy During Treatment

Weight loss on Wegovy follows a predictable trajectory during the dose escalation phase. Clinical data shows patients lose an average of 2-4% of body weight during the first 8 weeks at lower doses (0.25mg-1mg weekly), with weight reduction accelerating as the dose increases toward the therapeutic 2.4mg maintenance level [3].

By week 20—when most patients reach the full 2.4mg dose—average cumulative weight loss typically ranges from 6-8% of baseline body weight. The most substantial weight reduction occurs between weeks 20-52, with patients losing an additional 6-8% during this period when adhering to the prescribed regimen alongside dietary modifications [1].

Peak weight loss on Wegovy generally occurs around week 60-68 of continuous treatment, after which weight tends to stabilise at the new lower baseline. Individual responses vary considerably based on baseline BMI, adherence to lifestyle modifications, metabolic factors, and genetic predisposition to GLP-1 receptor agonist response. Our clinical team at Cured Pharmacy monitors patient progress through follow-up consultations to optimise outcomes and adjust treatment plans as needed.

Factors Influencing Weight Loss On Wegovy Outcomes in UK Patients

Baseline body composition significantly impacts weight loss on Wegovy, with higher starting BMI typically correlating with greater absolute weight reduction. However, percentage-based weight loss remains relatively consistent across BMI categories, averaging 12-16% in clinical trials regardless of initial weight [2].

Adherence to the prescribed injection schedule is critical—missing doses or inconsistent administration reduces treatment efficacy and may increase gastrointestinal side effects when resuming. The medication requires refrigeration between 2-8°C until first use, after which it may be stored at room temperature (up to 30°C) for up to 28 days, making proper storage education essential for optimal outcomes.

Concurrent lifestyle modifications amplify weight loss on Wegovy substantially. Trial data shows that participants engaging in structured dietary programmes and regular physical activity (150+ minutes weekly of moderate-intensity exercise) achieved 18-20% weight reduction compared to 10-12% in those using medication alone [3]. Our clinical team provides tailored lifestyle guidance alongside prescribing to maximise treatment benefits.

Metabolic and Genetic Factors Affecting Weight Loss On Wegovy

Individual variations in GLP-1 receptor expression and downstream signalling pathways contribute to the observed range of treatment responses. Approximately 10-15% of patients are considered 'low responders', achieving less than 5% weight reduction despite optimal adherence [2]. Genetic polymorphisms affecting incretin metabolism may partially explain this variability, though routine genetic testing is not currently recommended before initiating treatment.

Pre-existing metabolic conditions influence outcomes—patients with insulin resistance or polycystic ovary syndrome often experience enhanced benefits from semaglutide due to its insulin-sensitising effects. Conversely, hypothyroidism or certain medications (such as corticosteroids or atypical antipsychotics) may attenuate weight loss responses and require dose optimisation or additional interventions.

Treatment Active Ingredient Administration Starting Price
Wegovy Semaglutide 2.4mg Weekly injection £89.00
Mounjaro Tirzepatide Weekly injection £145.00
Saxenda Liraglutide 3mg Daily injection £68.00
Wegovy Oral Tablets Semaglutide (oral) Daily tablet £83.00
Orlistat Orlistat 120mg Three times daily £32.00
Mysimba Naltrexone/Bupropion Twice daily tablet £125.95

Weight Loss On Wegovy Compared to Other UK-Licensed Treatments

When evaluating weight loss on Wegovy against alternative pharmacological options, semaglutide demonstrates superior efficacy in head-to-head comparisons. The STEP 8 trial directly compared Wegovy to liraglutide 3mg (Saxenda), showing 15.8% versus 6.4% average weight reduction respectively over 68 weeks [4].

Tirzepatide (Mounjaro), a dual GIP/GLP-1 receptor agonist approved more recently in the UK, shows even greater weight reduction potential—the SURMOUNT-1 trial demonstrated average weight loss of 20.9% at the highest dose (15mg weekly) [4]. However, individual patient factors, side effect profiles, and prescriber assessment determine the most appropriate first-line treatment.

Orlistat, the most established weight management medication available from UK pharmacies, typically produces 5-7% weight reduction—substantially less than GLP-1 receptor agonists but with a different mechanism (lipase inhibition) and lower cost profile. At Cured Pharmacy, our prescribers consider medical history, treatment goals, budget constraints, and patient preferences when recommending the optimal weight management approach from our range of MHRA-licensed options.

Managing Side Effects During Weight Loss On Wegovy Treatment

Gastrointestinal symptoms represent the most common side effects during weight loss on Wegovy, affecting approximately 44% of patients in clinical trials [1]. Nausea typically peaks during dose escalation phases and diminishes with continued treatment as physiological tolerance develops. Taking the injection on a consistent day each week, staying well-hydrated, and consuming smaller, more frequent meals can significantly reduce symptom severity.

Constipation affects roughly 24% of patients and may persist throughout treatment due to semaglutide's effect on gastrointestinal motility [3]. Increasing dietary fibre intake, maintaining adequate fluid consumption (2-3 litres daily), and regular physical activity help manage this side effect. Patients experiencing severe or persistent constipation should consult their prescriber, as dose adjustment or temporary treatment interruption may be warranted.

Rare but serious adverse effects include pancreatitis (occurring in <0.2% of patients), gallbladder complications, and potential thyroid C-cell tumours (observed in rodent studies but not conclusively demonstrated in humans) [2]. Our clinical team at Cured Pharmacy conducts thorough medical history reviews during the online consultation process to identify contraindications, including personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Optimising Tolerability for Sustained Weight Loss On Wegovy

The gradual dose escalation protocol built into Wegovy prescribing guidelines serves specifically to improve gastrointestinal tolerability. Patients should not accelerate this schedule without prescriber guidance, as rapid dose increases substantially elevate the risk of treatment-limiting nausea and vomiting.

Injection technique influences both efficacy and side effect profile—administering Wegovy subcutaneously into the abdomen, thigh, or upper arm, rotating sites weekly, and ensuring the medication reaches room temperature before injection all contribute to improved tolerability. Our pharmacy team provides detailed administration guidance with each dispensing to support optimal treatment outcomes.

Accessing Weight Loss On Wegovy Through Cured Pharmacy UK

Wegovy is a prescription-only medication in the UK, requiring clinical assessment by a registered prescriber before dispensing. At Cured Pharmacy (GPhC registration 9012511), our streamlined online consultation process takes under 3 minutes and is reviewed by UK-registered clinicians who evaluate medical history, current medications, and suitability for semaglutide treatment.

We supply genuine UK-licensed Wegovy at £124.99 per pen, representing competitive pricing amongst registered UK pharmacies whilst maintaining full regulatory compliance and pharmaceutical quality standards. All medications are sourced through licensed UK wholesalers and stored in our temperature-controlled, GPhC-inspected facilities to ensure product integrity from manufacturer to patient.

Weight loss on Wegovy requires ongoing clinical monitoring—our service includes follow-up consultations to assess treatment response, manage side effects, and adjust therapy as needed. Patients receive discreet packaging with next-day delivery options, comprehensive administration instructions, and access to our pharmacist-led support line for any treatment-related questions. New patients can Save £20 on their first order using code Weightlossnew, making evidence-based weight management more accessible to UK adults meeting prescribing criteria.

Scientific References

  1. Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
  2. Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., ... & Lingvay, I. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971-984. [accessed 15 August 2026]
  3. Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., ... & Rubino, D. M. (2021). Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA, 325(14), 1403-1413. [accessed 15 August 2026]
  4. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., ... & Wadden, T. A. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425. [accessed 15 August 2026]
  5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
  6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
  7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.

Trusted by thousands

Real people, real results

Jane L.

"Brilliant. Lost 4 stone on mounjaro no side effects at all. Cured pharmacy are excellent. Always helpful pens sent out quickly always comes with needles and sterile wipes. If you want to go on GLP-1 go to cured pharmacy. So professional. Thank you cured pharmacy you changed my health and well being."

Ann-Marie

"I absolutely love this product, I have been using 2.5mg as maintenance dose and have managed to control my weight without any side effects and can still eat well balanced meals. The pharmacy is very efficient friendly and helpful I would not purchase from anywhere else."

Sacha W.

"So far I'm really impressed by my results it's crazy cause I'm not snacking like how I used to do and I see my face slimming down already and it's only been 2 and a half weeks. Can't wait to give my feedback in 5 months time thank you cured pharmacy."

Kimberly G.

"Mounjaro has corrected my hormonal weight gain during menopause. I am using it now to maintain that balance. The results for me have been exceptional!"

Jennifer

"Great really helps cure those nasty habits can't wait for my next mounjaro pen."

How it Works?

Select from our recommended UK-licensed medications.

1

Choose your treatment

Step 1: Choose your treatment from Cured Pharmacy

Select safe UK treatments. Quick answers.

2

Answer quick questions

Step 2: Answer quick consultation questions

We will deliver direct to you as quickly as tomorrow.

3

Get it delivered fast

Step 3: Fast discreet delivery to your door

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today

Once you complete a short online assessment you will be able to choose your preferred treatment from safe medically approved options tailored to you.

Start My Assessment

Returning Customer?

Log in to Your Account

Faq

How much weight can I realistically expect to lose on Wegovy in the UK?
Clinical trials show average weight loss on Wegovy of 14.9% over 68 weeks, though individual results vary from 5-20% based on adherence, baseline BMI, and lifestyle factors. All treatment requires prescriber assessment and ongoing monitoring.
When will I start seeing weight loss on Wegovy after starting treatment?
Most patients notice appetite reduction within 1-2 weeks and measurable weight loss by week 4-8. Substantial weight reduction typically occurs between weeks 20-68 as you reach the full 2.4mg maintenance dose.
Does weight loss on Wegovy continue after reaching the maintenance dose?
Weight loss on Wegovy typically continues until weeks 60-68, after which weight stabilises at the new lower baseline. Continuing treatment helps maintain weight loss, whilst discontinuation often leads to gradual weight regain.
Can I use Wegovy if I have type 2 diabetes for weight loss?
Yes, the STEP 2 trial demonstrated 9.6% average weight loss on Wegovy in adults with type 2 diabetes, along with improved blood glucose control. Your prescriber will assess suitability based on your complete medical history.
What happens to weight loss on Wegovy if I miss doses?
Missing doses reduces treatment efficacy and may increase side effects when resuming. If you miss a dose and the next scheduled dose is more than 2 days away, take it as soon as possible; otherwise, skip and resume your regular schedule.
Is weight loss on Wegovy permanent or will I regain weight after stopping?
Clinical data shows most patients regain 6-7% of body weight within one year of discontinuing Wegovy, as obesity is a chronic condition requiring ongoing management. Long-term treatment combined with sustained lifestyle changes optimises weight maintenance.
How does weight loss on Wegovy compare to Mounjaro in UK patients?
Wegovy produces average weight loss of 15%, whilst Mounjaro (tirzepatide) demonstrates slightly higher reductions of 15-21% depending on dose in clinical trials. Both require prescription and individual suitability assessment by a UK clinician.
Do I need to follow a special diet to achieve weight loss on Wegovy?
Whilst Wegovy reduces appetite independently, combining it with a structured dietary programme and regular exercise (150+ minutes weekly) can increase weight loss from 10-12% to 18-20% based on clinical trial data.
Tarun Kumar, Prescribing Pharmacist

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Reviewed on: June 03, 2026

Last reviewed: 15 August 2026

Last updated on 15 August 2026.

Review History

Our experts continually monitor new findings in health and medicine, and we update our articles when new information becomes available.

Why this page was updated on 15 August 2026

Content checked and updated as part of our periodic review, to ensure accuracy and currentness.

Current version (15 August 2026)

Edited by: The Editorial Team

Medically reviewed by:

Tarun Kumar, GPhC No. 2233073, Prescribing Pharmacist


How we source info.

When we present you with stats, data, opinion or a consensus, we'll tell you where this came from.